Crossmark

Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study

Crossref DOI link: https://doi.org/10.1186/s12933-021-01220-x

Published Online: 2021-01-29

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Andrew

Wong, Nathan D.

Razipour, Aryabod

McElhinney, Priscilla A.

Commandeur, Frederic

Cadet, Sebastien J.

Gransar, Heidi

Chen, Xi

Cantu, Stephanie

Miller, Robert J. H.

Nerlekar, Nitesh

Wong, Dennis T. L.

Slomka, Piotr J.

Rozanski, Alan

Tamarappoo, Balaji K.

Berman, Daniel S.

Dey, Damini http://orcid.org/0000-0003-2236-6970
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct00927693 at ClinicalTrials.gov

Documents that mention this clinical trial

Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study
https://doi.org/10.1186/s12933-021-01220-x
Funding

Funding for this research was provided by:

National Heart, Lung, and Blood Institute (1R01HL133616, 1R01HL148787-01A1)
License Information

Text and Data Mining valid from 2021-01-29

Version of Record valid from 2021-01-29
More Information

Article History

Received: 6 November 2020

Accepted: 17 January 2021

First Online: 29 January 2021

Ethics approval and consent to participate

: This research was approved by the CSMC Institutional Review Board and all participants provided signed informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below